$BSX (BOSTON SCIENTIFIC) EARNINGS CONFIRM OUR SHORT SELL THESIS
We have been short on $MDT (Medtronics) with the first scale in at $36.20 and more aggressive entry at $38.00. $BSX earnings show weakness in both stents and implantable cardiac devices. Going forward guidance for US is quite a bit lower than expected. This confirms our thesis and we will stay short on $MDT. www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD Every closed trade since 2007, without exception, is included in the performance results. Number of winning positions: 162 Number of losing